Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System
NCT07687485
Cardiovascular Diseases, Cardiovascular Diseases (CVD)
View Trial DetailsNCT Number: NCT07735689
The objective of this study is to evaluate the efficacy of the modified shock index (MSI) in predicting the incidence of postoperative cardiovascular events (PCEs) in patients with pre-existing cardiac disease undergoing non-cardiac surgery. A retrospective analysis was performed on the clinical data of patients who underwent gastric, colorectal, and hepatobiliary surgeries at Union Hospital Affiliated to Fujian Medical University between January 2020 and December 2025. Baseline characteristics, intraoperative vital signs, occurrence of postoperative cardiac complications, and total postoperative hospital stay were reviewed and summarized to assess the predictive performance of the MSI for PCEs in this patient population.
Trial opening soon.
Get Notified45 year and older
All sexes
Observational
This study aims to evaluate the efficacy of the modified shock index (MSI) in predicting postoperative cardiovascular events (PCEs) in cardiac patients undergoing non-cardiac surgery. A retrospective analysis was conducted on clinical data from patients who underwent gastrointestinal and hepatobiliary surgeries at Fujian Medical University Union Hospital between January 2020 and December 2025. Baseline characteristics, intraoperative vital signs, occurrence of cardiac complications, and total postoperative hospital stay were analyzed to determine the optimal MSI cutoff values, sensitivity, specificity, and Youden's index for PCE prediction. The study further elucidates pathophysiological mechanisms linking MSI thresholds to organ hypoperfusion, providing an evidence-based tool for individualized perioperative hemodynamic management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(3) Presence of any of the following: history of heart disease; elevated BNP or cardiac troponin within 30 days before surgery; or at least two cardiac risk factors.
(4) Complete electronic medical records available.
Exclusion criteria
Time frame: 1-7 days after surgery
Myocardial injury/infarction: Postop cTnT > upper limit, ± new ischemic ECG, new wall motion abnormality on echocardiography, or CXR pulmonary edema.
Acute heart failure: Dyspnea/crackles needing diuretic/vasodilator, plus ≥1: BNP >400 pg/mL, NT-proBNP >1800 pg/mL, CXR congestion/edema, or echocardiographic LVEF drop ≥10% or acute diastolic worsening.
Serious arrhythmia: Sustained VT/VF needing urgent intervention; new rapid atrial fibrillation with hemodynamic instability; high-degree atrioventricular block needing temporary pacing; or resuscitated cardiac arrest.
Cardiac death: Death from above events, supported by cTnT, BNP, ECG, echocardiography, or CXR, excluding definite non-cardiac causes.
Time frame: 1-7 days after surgery
Time frame: 30 days after surgery and 180 days after surgery
Time frame: 30 days after surgery and 180 days after surgery
Contact information is provided by the study sponsor or research team.
Fujian Medical University Union Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07687485
Cardiovascular Diseases, Cardiovascular Diseases (CVD)
View Trial DetailsNCT07679763
Cardiovascular Diseases, Cardiovascular Diseases (CVD)
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07604207
Cardiovascular Diseases, Cardiovascular Diseases (CVD)
View Trial DetailsNCT06683534
Body Weight, Cardiovascular Diseases
Wauwatosa, Wisconsin, United States
View Trial Details